<DOC>
	<DOCNO>NCT00006207</DOCNO>
	<brief_summary>The purpose study determine whether vaginal gel PRO 2000/5 cause irritation use daily . Studies show PRO 2000/5 safe well tolerated vaginal gel healthy woman sexually active . However , determine side effect skin vaginal area might sexually active woman .</brief_summary>
	<brief_title>Safety Tolerability Vaginal Gel PRO 2000/5</brief_title>
	<detailed_description>Vaginal microbicides design inhibit sexual transmission HIV-1 disease pathogen . Two Phase I clinical trial conduct evaluate safety tolerance gel , PRO 2000/5 , sexually abstinent volunteer . Both demonstrated multiple application gel safe well tolerate healthy , sexually abstinent woman clear association use gel epithelial disruption indicate . Because genital ulceration inflammation may increase risk HIV infection , additional clinical evaluation PRO 2000/5 gel warrant , especially study participant active sexual behavior . Participants apply PRO 2000/5 gel intravaginally either twice daily 14 day . HIV-negative participant sexually active cohort ( Cohorts A1-A4 ) instruct engage vaginal intercourse least twice week . Participants HIV-positive cohort ( Cohort B1 ) abstain sexual intercourse dose period . Researchers conduct physical exam see gel harmful effect woman 's vulva , vagina , cervix . Women male partner question gel usage .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<criteria>Inclusion Criteria Volunteers may eligible study : Are female 1845 year age . Are willing able complete daily study record . Are willing undergo clinical exam test . Either regular menstrual period menstruate due use hormone . Agree stop use female barrier method birth control study . Additionally , volunteer may eligible HIVnegative group study : Have change use hormonal birth control last 3 month . Are HIVnegative . Have single male partner lowrisk HIV infection agree ask consent . Agree follow : To vaginal intercourse 2 time week ; use condom provide study act intercourse ; use gel direct ; similar study ; receive oral sex ; use IV drug , except medical treatment ; use vaginal product ; douche ; use vaginal drying agent . Additionally , volunteer may eligible HIVpositive group study : Are HIVpositive . Have CD4 count great 200 cells/mm3 . Have normal Pap smear screening . Are stable antiHIV drug therapy . Agree sexual intercourse study . Have HIV care qualify medical caregiver . Agree allow study staff access HIV medical care information . Agree follow : To use gel direct ; use IV drug medical treatment ; use vaginal product ; participate similar study ; receive oral sex ; douche ; use vaginal drying agent . Exclusion Criteria Volunteers eligible study : Are menopausal . Have certain liver , kidney , blood problem . Have genital problem sore . Are allergic anything use study , include latex . Have use spermicide condom treat spermicide within week enrollment . Have another drug study within past 30 day . Have participate trial study gel permanently discontinue . Have IUD begin use hormonal birth control , abnormal Pap smear , pregnancy , abortion , gynecologic surgery , breakthrough menstrual bleeding , vaginal bleeding follow sexual intercourse , last 3 month . Have receive treatment sexually transmit disease past 3 month . Show sign , pelvic exam , indicate sexually transmit disease genital tract problem . Used IV drug , except medical reason , within past year . Received antibiotic last 14 day . Have reaction anticoagulant ( warfarin heparin ) . Are pregnant breastfeeding . Have positive urine culture .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2003</verification_date>
	<keyword>HIV Seropositivity</keyword>
	<keyword>Dose-Response Relationship , Drug</keyword>
	<keyword>HIV Seronegativity</keyword>
	<keyword>Mucous Membrane</keyword>
	<keyword>Ulcer</keyword>
	<keyword>Vagina</keyword>
	<keyword>Anti-HIV Agents</keyword>
	<keyword>Sexual Abstinence</keyword>
	<keyword>Irritants</keyword>
	<keyword>PRO 2000</keyword>
</DOC>